Aytu BioPharma Inc. (NASDAQ:AYTU) Given Consensus Recommendation of “Hold” by Analysts

Shares of Aytu BioPharma Inc. (NASDAQ:AYTU) have earned an average recommendation of “Hold” from the five analysts that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $9.3333.

A number of research firms have recently commented on AYTU. Maxim Group cut their price objective on shares of Aytu BioPharma from $9.00 to $7.00 and set a “buy” rating for the company in a research report on Thursday, September 25th. Wall Street Zen downgraded shares of Aytu BioPharma from a “buy” rating to a “hold” rating in a report on Friday, September 26th. Ascendiant Capital Markets boosted their price target on shares of Aytu BioPharma from $12.50 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, December 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aytu BioPharma in a research report on Friday, January 9th. Finally, Zacks Research raised Aytu BioPharma from a “strong sell” rating to a “hold” rating in a research note on Monday, November 24th.

Aytu BioPharma Price Performance

Shares of NASDAQ AYTU opened at $2.61 on Thursday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.08 and a current ratio of 1.23. Aytu BioPharma has a fifty-two week low of $0.95 and a fifty-two week high of $3.07. The stock has a market cap of $26.60 million, a PE ratio of -0.86 and a beta of 0.32. The stock has a fifty day moving average of $2.40 and a 200-day moving average of $2.32.

Aytu BioPharma (NASDAQ:AYTU) last issued its earnings results on Thursday, November 13th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.02). Aytu BioPharma had a positive return on equity of 17.86% and a negative net margin of 20.52%.The company had revenue of $13.89 million during the quarter, compared to the consensus estimate of $17.92 million.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Daytona Street Capital LLC purchased a new stake in Aytu BioPharma in the fourth quarter valued at approximately $26,000. Dimensional Fund Advisors LP bought a new position in shares of Aytu BioPharma in the 3rd quarter worth $58,000. FNY Investment Advisers LLC raised its position in shares of Aytu BioPharma by 24,207.7% during the 4th quarter. FNY Investment Advisers LLC now owns 31,600 shares of the company’s stock valued at $82,000 after buying an additional 31,470 shares in the last quarter. Persistent Asset Partners Ltd purchased a new stake in shares of Aytu BioPharma during the 3rd quarter valued at $117,000. Finally, Two Sigma Investments LP grew its position in Aytu BioPharma by 96.2% in the third quarter. Two Sigma Investments LP now owns 68,736 shares of the company’s stock worth $129,000 after acquiring an additional 33,701 shares in the last quarter. 33.49% of the stock is currently owned by institutional investors.

Aytu BioPharma Company Profile

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.